Evidence map›Paper›PMID 34880295›Full record

ArticleScientific reports2021

Emergence of novel combinations of SARS-CoV-2 spike receptor binding domain variants in Senegal.

Ambroise D Ahouidi, Mary A Rodgers, Abdou Padane, Nafissatou Leye, Ana Olivo, Moustapha Mbow, Aminata Mboup, Papa Alassane Diaw, Aminata Dia, Barbara Harris and 8 more

Abstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ambroise D Ahouidi *Institute for Health Research, Epidemiological Surveillance and Training (IRESSEF), Dakar, Senegal. ambroise.ahouidi@iressef.org.
Mary A Rodgers *Abbott Global Surveillance Program, Abbott Laboratories, Abbott Park, IL, USA. mary.rodgers@abbott.com.
Abdou PadaneInstitute for Health Research, Epidemiological Surveillance and Training (IRESSEF), Dakar, Senegal.
Nafissatou LeyeInstitute for Health Research, Epidemiological Surveillance and Training (IRESSEF), Dakar, Senegal.
Ana OlivoAbbott Global Surveillance Program, Abbott Laboratories, Abbott Park, IL, USA.
Moustapha MbowInstitute for Health Research, Epidemiological Surveillance and Training (IRESSEF), Dakar, Senegal.
Aminata MboupInstitute for Health Research, Epidemiological Surveillance and Training (IRESSEF), Dakar, Senegal.
Papa Alassane DiawInstitute for Health Research, Epidemiological Surveillance and Training (IRESSEF), Dakar, Senegal.
Aminata DiaInstitute for Health Research, Epidemiological Surveillance and Training (IRESSEF), Dakar, Senegal.
Barbara HarrisAbbott Global Surveillance Program, Abbott Laboratories, Abbott Park, IL, USA.
Yacine Amet Dia PadaneInstitute for Health Research, Epidemiological Surveillance and Training (IRESSEF), Dakar, Senegal.
Gora LoInstitute for Health Research, Epidemiological Surveillance and Training (IRESSEF), Dakar, Senegal.
Todd V MeyerAbbott Global Surveillance Program, Abbott Laboratories, Abbott Park, IL, USA.
Cyrille K DiedhiouInstitute for Health Research, Epidemiological Surveillance and Training (IRESSEF), Dakar, Senegal.
Diabou DiagneInstitute for Health Research, Epidemiological Surveillance and Training (IRESSEF), Dakar, Senegal.
Ndeye Coumba Toure KaneInstitute for Health Research, Epidemiological Surveillance and Training (IRESSEF), Dakar, Senegal.
Gavin ClohertyAbbott Global Surveillance Program, Abbott Laboratories, Abbott Park, IL, USA.
Souleymane MboupInstitute for Health Research, Epidemiological Surveillance and Training (IRESSEF), Dakar, Senegal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages that carry mutations in the spike gene are of concern for potential impact to treatment and prevention efforts. To monitor for new SARS-CoV-2 mutations, a panel of specimens were sequenced from both wave one (N = 96), and wave two (N = 117) of the pandemic in Senegal by whole genome next generation sequencing. Amongst these genomes, new combinations of SARS-CoV-2 spike mutations were identified, with E484K + N501T, L452R + N501Y, and L452M + S477N exclusively found in second wave specimens. These sequences are evidence of local diversification over the course of the pandemic and parallel evolution of escape mutations in different lineages.

Indexed as

COVID-19HumansMutationProtein BindingProtein DomainsSARS-CoV-2SenegalSpike Glycoprotein, CoronavirusSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID34880295
PMCPMC8655062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.